The Mesoblast limited (ASX:MSB) share price was on fire in November but has been tipped to go even higher from here…
The post The Mesoblast (ASX:MSB) share price jumped 33% in November and could go even higher appeared first on Motley Fool Australia. –
The Mesoblast limited (ASX: MSB) share price was one of the best performers on the ASX 200 in November.
The biotechnology company’s shares raced a massive 33% higher over the month.
Why did the Mesoblast share price zoom higher in November?
The catalyst for the strong gain by the Mesoblast share price in November was the announcement of a major deal with pharma giant Novartis.
That deal has seen Novartis sign an exclusive worldwide license and collaboration agreement for the development, manufacture, and commercialisation of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L for the treatment of COVID-19 Acute Respiratory Distress Syndrome (ARDS).
According to the release, Novartis will pay US$50 million upfront and then upwards of US$1.25 billion in milestone payments.
This news went down very well with analysts at Bell Potter. They described it as a “fantastic deal” for Mesoblast. Furthermore, they like that it provides greater certainty in relation to the manufacturing and commercialisation of the product for COVID-19 ARDS.
Can the Mesoblast share price go higher?
This month, Bell Potter has looked closer at the deal and adjusted its price target accordingly.
The broker has a (speculative) buy rating and $7.40 price target on the company’s shares. This is up from $7.00 previously and compares to its last close price of $4.43.
According to the note, Bell Potter has lifted its FY 2021 earnings forecasts to reflect the deal.
It commented: “Over the next 12 months we expect MSB to receive US$32.5m in milestones from partner Grunenthal for back pain product and US$105m from partner NVS for successful results from Phase 3 trial and approval for COVID-19 ARDS for remestemcel-L. In addition, US$35m is available to MSB on its existing debt facilities, which provides a runway to at least year end FY22.”
What else did it say?
There are also a number of catalysts on the horizon which it feels could take its shares higher.
“Phase 3 COVID-19 ARDS trial has surpassed recruitment of 180 patients required for third and final interim analysis, which we expect to be completed by mid-Dec’20. The trial is now expected to complete recruitment in early 1QCY21, with results later in 1QCY21. Results from both Phase 3 back pain and heart failure trials are expected in Dec’20, which we expect will be key catalysts for the stock, given these indications account for the majority of our valuation for MSB,” it concluded.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- ASX 200 flat on Wednesday
- Why Laybuy, Mesoblast, Sandfire, & Telix shares are charging higher
- ASX 200 down 0.2%: Zip’s November update, Mesoblast jumps, Westpac’s asset sale
- Mesoblast (ASX:MSB) share price jumps 19% on FDA update
- Flight Centre and Mesoblast were among the most traded shares on the ASX last week
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.